BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is ...
Hosted on MSN
Novel embolization-on-a-chip model allows testing various embolic agent classes to treat liver cancer
Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This novel ...
Los Angeles, CA – September 3, 2025 - Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in ...
Balt Inc, a global technology innovator in the neurovascular field working closely with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ...
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid liquid embolic agent. Squid is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results